AKR1C2

Across TCGA pan-cancer cohorts, AKR1C2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKR1C2 data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AKR1C2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKR1C2 expression acts as an unfavorable survival marker.

LUAD, PDAC, and CCRCC are the cancer types where AKR1C2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.740	0.994	.001	46	view →
PDAC	OS	Median	II,III,IV	0.712	0.943	<.001	36	view →
CCRCC	DFS	Tertile	III,IV	0.198	0.887	.024	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
HNSC	OS	Median	All	0.618	0.775	.023	4	view →
UCEC	DFS	Quartile	All	0.798	0.966	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AKR1C2–LUAD (DFS)

Open the LUAD breakdown →